- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02213237
The Application of SERS and Metabolomics in Sepsis
Study Overview
Status
Conditions
Detailed Description
Sepsis is a serious medical condition caused by an overwhelming immune response to infection. Different series of chemicals released into the blood to fight infection trigger systemic inflammation, which is also called systemic inflammatory syndrome, SIRS. Sepsis is one of the major public health issues, which are characterized with high cost and high mortality. Epidemiological studies suggest that there are approximately 300 sepsis cases in per 100,000 population; accounting for 2% of all hospital admissions and up to 30% of intensive care unit admissions. Sepsis is the leading cause of death in critically ill patients. The mortality is as high as 20% in patients with severe sepsis and 46% when septic shock develops. Despite recent advances in sepsis treatment, including early goal-directed therapy, low-dose corticosteroid use, protective ventilation, intensive glucose control and activated protein C use, sepsis is still a major challenge for clinical physicians.
Early appropriate antibiotic therapy targeting at the causative pathogen is always crucial to the successful treatment of severe sepsis and septic shock. However, blood culture, the current standard for microbiological diagnosis, can't provide the instant information of pathogens identification at the right beginning of sepsis.
It usually takes 5-7 days to wait for the final report and even much longer for some slow-growth bacteria or yeasts. Moreover, the yield positive rate is low. Only 30% positive results were reported in patients with sepsis and 50 to 60% in septic shock. Some microorganisms are present in the blood in very small numbers and must have longer time to reproduce and grow to quantities that can be detected. Some microorganisms are difficult to grow and special nutrient media may be needed. Viruses cannot be also detected using blood culture bottles designed to grow bacteria. Besides, antimicrobial therapy in the preceding two weeks may prevent pathogen growth.
Since the time to initiation of appropriate antimicrobial therapy is the strongest predictor of mortality, the antibiotics are usually started "empirically" (ie. based on doctors' experience) with broad spectrum and adjusted according to the clinical response. For lack of precise data, inadequate infection control may encounter leading to poor prognosis, and furthermore adverse effects of antibiotics such as organ toxicity and collateral damage (i. e., selection of drug-resistant organisms and the unwanted development of colonization or infection with multidrug-resistant organisms) occurs.
Using the SERS and fluorescent microscopy-based high-speed diagnosis platform for clinical microbiology may help to solve this problem. The specific aims of the subproject are listed as below:
- To develop a comprehensive protocol of pretreatment of the complex blood sample from the patients with sepsis as the preparation for SERS detection.
- To identify the causative bacteria or yeasts in the blood by the high-speed diagnosis platform based on SERS to guide the initial antibiotics treatment in sepsis.
- To examine the susceptibility of the causative pathogen to various antibiotics to guide the initial antibiotics treatment in sepsis.
- To quantify the bacterial counts in blood to explore the relationship between the load (virulence) of pathogen and clinical course, transmissibility, and antibiotic resistance in patients with sepsis.
- To compile a database of SERS spectra of clinical microbiology, including bacteria, yeasts and fungi that are the common causative pathogens of sepsis.
The investigators expect this novel technique based on SERS and fluorescent optical microscopy will play a crucial role in modern sepsis treatment, not only bringing great impact on mortality reduction, cost control, but also alleviating the problem of growing resistant trains from the inappropriate use of antibiotics.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Yin-Yi Han, MD
- Phone Number: +886-9-72651405
- Email: Noviahan@gmail.com
Study Locations
-
-
-
Taipei, Taiwan
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Yin-Yi Han, MD
- Phone Number: +886-9-72651405
- Email: Noviahan@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Any hospitalized patient with
- Septic shock
- Before the use of parenteral or systemic antimicrobial therapy
Exclusion Criteria:
- Pregnant women
- Organ transplantation
- Cancer
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of the causal pathogenic organism of sepsis subjects as well as the drug sensitivity test by SERS technique.
Time Frame: 5-6 hours
|
By the SERS technique may measure one time as below:
|
5-6 hours
|
Collaborators and Investigators
Investigators
- Study Chair: Yin-Yi Han, MD, National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201107031 RC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
-
Inverness Medical InnovationsCompletedSepsis | Systemic Inflammatory Response Syndrome | Severe Sepsis | Sepsis SyndromeUnited States